BETA CELL COMPENSATORY FACTORS IN INSULIN RESISTANCE - STUDIES IN PREGNANCY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究得到了GCRC学生奖的支持。 其重点关注先前批准的IRB方案（12681）的子项目之一。 它侧重于该提案次级项目4的一个方面。 胰岛素抵抗（IR）是2型糖尿病和心血管疾病的一个众所周知的组成部分。 然而，短期IR是怀孕等状态下的必要生理现象。 IR期间正常葡萄糖水平的维持依赖于分泌胰岛素的β细胞增加其输出以克服IR中发生的胰岛素抵抗的能力。虽然被认为是葡萄糖，但有理由怀疑葡萄糖只是该机制的一部分，如果有的话。 替代信号的可能性，β细胞补偿因子（BCCF）将使用妊娠自发IR的生理现象进行研究，并将其与短期药物诱导IR的实验模型进行比较。此外，蛋白质组学的初步研究将用于启动潜在的新BCCF分子的鉴定。 了解β细胞补偿IR的信号可能会为预防或治疗2型糖尿病带来新的治疗可能性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is supported by a GCRC student award. It is focused upon one of the subprojects of a previously approved IRB protocol (12681). It focuses upon one aspect of subproject 4 of that proposal. Insulin resistance (IR) is a well-known component of Type 2 diabetes and cardiovascular disease. However, short-term IR is a necessary physiological phenomenon in states such as pregnancy. Maintenance of normal glucose levels during IR is dependent upon the ability of the insulin-secreting beta cells to increase their output in order to overcome the resistance to insulin action that occurs in IR. This proposal will study the physiology of the compensatory increase in insulin secretion in IR. The signal to the beta cells to increase insulin secretion during IR is not well defined; though thought to be glucose, there is reason to suspect that glucose is only part of the mechanism, if at all. The possibility of alternative signaling, beta cell compensatory factors (BCCF) will be studied using the physiological phenomenon of spontaneous IR of pregnancy and comparing it to an experimental model of short-term, drug-induced IR. In addition, preliminary studies of proteomics will be used to initiate identification of potentially new BCCF molecules. Understanding signals for beta cell compensation to IR may lead to new therapeutic possibilities for the prevention or treatment of Type 2 diabetes.